

**A Prospective Randomized Controlled Study Using
Optical Coherence Tomography to Evaluate the
Strut Coverage of Sirolimus-, Paclitaxel-,
Zotalorimus-Eluting Coronary Stents For Long
Lesions Requiring Overlapping**

ODESSA-OCT for DES Safety

Authors: G. Guagliumi¹, G. Musumeci¹, V. Sirbu¹, N. Suzuki³, G. Biondi Zoccai², L. Mihalcsik¹, A. Matiashvili¹, A. Trivisonno¹, N. Lortkipanidze¹, L. Fiocca¹, J. Coletta³, H. Bezerra³, O. Valsecchi¹, M. Costa³

¹ Division of Cardiology, Ospedali Riuniti di Bergamo, Italy ² Division of Cardiology, University of Turin, Italy

³ Case Western Reserve University, Cleveland, OH, US

ODESSA

Prospective, Randomized, Controlled Study

Long lesions (> 20 mm in length) requiring stents in overlap

77 pts /189 stents Randomization 2:2:2:1

2.4 ± 0.6 stent/lesion

Taxus
N=22

Cypher
N=22

Endeavor
N=22

Libertè BMS
N=11

*Primary end-point: proportion of stent struts uncovered and/or malapposed at overlap in OCT at 6 month (BMS vs DES and among DES) **


QCA, IVUS and OCT

*Independent Core Lab **BLIND** to the treatment assignment*

University Hospitals Cardialysis Cleveland, OH

* All patients in dual antiplatelet therapy

Primary End Points




Embedded


**Protruding
Covered**

**Protruding Uncovered
Malapposed**


Primary Endpoint: Overlap Proportion of uncovered and/or malapposed struts in BMS vs DES



Secondary Endpoint: Overlap Proportion of uncovered and/or malapposed struts by stent type




Non-overlap Proportion of uncovered and/or malapposed struts by stent type



% Intimal Obstruction by Segments: OCT and IVUS

■ OCT % NIH ■ IVUS % NIH



Overlap length (mm)	3.6 ± 1.8	3.1 ± 1.9	3.8 ± 2.2	3.9 ± 4.0
% IH obstruction	19.3 ± 14.1	31.5 ± 14.3	45.2 ± 16	57.8 ± 25.2

Based on ANOVA test and Kruskal-Wallis test

Conclusions

The **ODESSA** trial demonstrated:

- Feasibility of using intravascular OCT in prospective clinical trials
- >90% strut coverage at 6-month follow-up
- Trend towards higher incidence of uncovered and malapposed struts at the OL site of DES than in BMS
- Different degrees of strut coverage and NIH among DES platforms:

SES : Highest rate of uncovered and malapposed struts (*OL = non-OL*)
Lowest degree of NIH (*OL > non-OL*)

ZES: Lowest rate ($\approx 0\%$) of uncovered and malapposed struts (*OL = non-OL*)
Highest degree of NIH (*OL > non-OL*)

PES: Higher incidence of uncovered and malapposed struts (*OL > non-OL*)
Intermediate degree of NIH (*OL > non-OL*)